Home › Melanoma › Florida › Orlando
Melanoma clinical trials in Orlando, FL
15 studies for Melanoma are looking for participants at sites in and around Orlando (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 2
- AdventHealth Medical Group Oncology Research at Celebration, Kissimmee · 16 mi away
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
RecruitingPhase 2
- Nemours Children's Hospital, Orlando
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
RecruitingPhase 3
- Orlando Health Cancer Institute, Orlando
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
RecruitingPhase 3
- Orlando Health Cancer Institute, Orlando
- Health Central, Ocoee · 10 mi away
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
RecruitingPhase 1
- AdventHealth, Orlando
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
RecruitingPhase 2
- Orlando Health Cancer Institute, Orlando
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
RecruitingPhase 1
- Sarah Cannon Research Institute - Florida Cancer Specialists, Orlando
Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
- AdventHealth Orlando, Orlando
- Arnold Palmer Hospital for Children, Orlando
- Nemours Children's Hospital, Orlando
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- AdventHealth Celebration, Celebration · 17 mi away
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecruitingPhase 1/2
- Clermont Oncology Center, Clermont · 24 mi away
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
RecruitingPhase 1
- Florida Cancer Specialists - Lake Nona, Orlando
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
RecruitingPhase 1/2
- Orlando Health Cancer Institute (Melanoma/NSCLC), Orlando
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RecruitingPhase 1/2
- Orlando Health Cancer Institute, Orlando
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
RecruitingPhase 3
- Orlando Health Cancer Institute, Orlando
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RecruitingPhase 1/2
- Research Site 137, Orlando
- Research Site 118, Celebration · 17 mi away
About Melanoma
Melanoma is the most serious type of skin cancer. Most have a black or black-blue area. Learn the 'ABCDE' of what to watch for and treatment options.
More about Melanoma on MedlinePlus
Melanoma trials in other cities
- Houston, TX59 studies
- New York City, NY38 studies
- Los Angeles, CA34 studies
- Nashville, TN32 studies
- Pittsburgh, PA31 studies
- Boston, MA25 studies
- Philadelphia, PA23 studies
- San Francisco, CA22 studies
- Atlanta, GA21 studies
- Columbus, OH21 studies
- Salt Lake City, UT21 studies
- Durham, NC21 studies
Other studies in Orlando
- Non-Small Cell Lung Cancer44 studies
- Metastatic Cancer29 studies
- Obesity29 studies
- Cancer (all types)25 studies
- Alzheimer's Disease25 studies
- Overweight25 studies
- Type 2 Diabetes24 studies
- Breast Cancer23 studies
- Ulcerative Colitis23 studies
- Ovarian Cancer22 studies
- Lung Cancer21 studies
- Colorectal Cancer19 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.